These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 6600985)

  • 1. Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors.
    Kefford RF; Fox RM
    Cancer Chemother Pharmacol; 1983; 10(2):73-8. PubMed ID: 6600985
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of acute lymphoblastic leukemia with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Mitchell BS; Koller CA; Kelley WN
    Adv Exp Med Biol; 1979; 122B():347-50. PubMed ID: 317568
    [No Abstract]   [Full Text] [Related]  

  • 3. Deoxy-ATP accumulation in adenosine deaminase-inhibited human B and T lymphocytes.
    Gruber HE; Cohen AH; Firestein GS; Redelman D; Bluestein HG
    Adv Exp Med Biol; 1986; 195 Pt A():503-7. PubMed ID: 3487921
    [No Abstract]   [Full Text] [Related]  

  • 4. [Successful treatment with 2'-deoxycoformycin in a case of adult T-cell leukemia].
    Ishii M; Yamaguchi K; Yul LS; Oda T; Takatsuki K
    Rinsho Ketsueki; 1986 May; 27(5):780-3. PubMed ID: 3018324
    [No Abstract]   [Full Text] [Related]  

  • 5. Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia.
    Prentice HG; Smyth JF; Ganeshaguru K; Wonke B; Bradstock KF; Janossy G; Goldstone AH; Hoffbrand AV
    Lancet; 1980 Jul; 2(8187):170-2. PubMed ID: 6105339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of adenosine deaminase inhibitors on the apparent rate of phosphorylation of deoxyadenosine.
    Deibel MR; Coleman MS; Hutton JJ
    Biochem Med; 1981 Jun; 25(3):288-97. PubMed ID: 6973972
    [No Abstract]   [Full Text] [Related]  

  • 7. Adenosine deaminase in malaria infection: effect of 2'-deoxycoformycin in vivo.
    Webster HK; Wiesmann WP; Pavia CS
    Adv Exp Med Biol; 1984; 165 Pt A():225-9. PubMed ID: 6609525
    [No Abstract]   [Full Text] [Related]  

  • 8. The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Smyth JF; Paine RM; Jackman AL; Harrap KR; Chassin MM; Adamson RH; Johns DG
    Cancer Chemother Pharmacol; 1980; 5(2):93-101. PubMed ID: 6970630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of K and NK lymphocyte cytotoxicity by an inhibitor of adenosine deaminase and deoxyadenosine.
    Grever MR; Siaw MF; Coleman MS; Whisler RL; Balcerzak SP
    J Immunol; 1983 Jan; 130(1):365-9. PubMed ID: 6600187
    [No Abstract]   [Full Text] [Related]  

  • 10. Current status of clinical trials of m-AMSA, dihydroxyanthracenedione, and deoxycoformycin.
    Macdonald JS; Marsoni S; Bruno S; Poster D
    Recent Results Cancer Res; 1982; 80():323-30. PubMed ID: 6977170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of arabinosyladenine metabolism by 2'-deoxycoformycin in the therapy of human acute leukemia.
    Plunkett W; Nowak B; Feun LG; Benjamin RS; Keating M; Freirich EJ
    Adv Exp Med Biol; 1984; 165 Pt B():345-50. PubMed ID: 6372382
    [No Abstract]   [Full Text] [Related]  

  • 12. In vivo inhibition of adenosine deaminase by 2'-deoxycoformycin in mouse blood and leukemia L1210 cells.
    Agarwal RP
    Biochem Pharmacol; 1980 Feb; 29(2):187-93. PubMed ID: 6965857
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical, pharmacologic, and immunologic effects of 2'-deoxycoformycin.
    Cummings FJ; Crabtree GW; Wiemann MC; Spremulli EN; Parks RE; Calabresi P
    Clin Pharmacol Ther; 1988 Nov; 44(5):501-9. PubMed ID: 3263248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated T lymphocytes resist the toxic effects of the adenosine deaminase inhibitor, 2-deoxycoformycin.
    Kotb M; Veit BC
    Cell Immunol; 1982 Sep; 72(1):64-76. PubMed ID: 6983389
    [No Abstract]   [Full Text] [Related]  

  • 15. Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Hershfield MS; Kurtzberg J; Harden E; Moore JO; Whang-Peng J; Haynes BF
    Proc Natl Acad Sci U S A; 1984 Jan; 81(1):253-7. PubMed ID: 6607471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenosine and hypoxic vasodilatation.
    Dóra E
    J Cereb Blood Flow Metab; 1985 Dec; 5(4):621-4. PubMed ID: 3877069
    [No Abstract]   [Full Text] [Related]  

  • 17. Biochemical changes induced in hairy-cell leukemia following treatment with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Johnston JB; Begleiter A; Pugh L; Leith MK; Wilkins JA; Cavers DJ; Israels LG
    Cancer Res; 1986 Apr; 46(4 Pt 2):2179-84. PubMed ID: 2418965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemolysis in mice treated with deoxycoformycin, an inhibitor of adenosine deaminase.
    Smith CM; Belch A; Henderson JF
    Biochem Pharmacol; 1980 Apr; 29(8):1209-10. PubMed ID: 6966932
    [No Abstract]   [Full Text] [Related]  

  • 19. Energy metabolism in adenosine deaminase-inhibited human erythrocytes.
    Buc HA; Thuillier L; Hamet M; Garreau F; Moncion A; Pérignon JL
    Clin Chim Acta; 1986 Apr; 156(1):61-9. PubMed ID: 3486057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of ADA inhibition on B cell differentiation in the rat.
    Barton RW
    Adv Exp Med Biol; 1986; 195 Pt A():525-9. PubMed ID: 3524140
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.